Last updated: August 27, 2026
MSD International Business GmbH is best analyzed as part of the global MSD organization, known in the United States as Merck & Co., Inc. Public filings do not report the entity as a standalone operating segment with separate revenue, product sales, R&D spending or market share. Its commercial and intellectual-property significance therefore derives primarily from the broader MSD group, particularly its oncology, vaccines, hospital, immunology and animal-health businesses.
MSD’s strongest assets are Keytruda, Gardasil and a growing portfolio of oncology and specialty medicines. The company’s main competitive risks are Keytruda’s eventual loss of exclusivity, intense checkpoint-inhibitor competition, pricing pressure in vaccines and biosimilar development against large biologic products.
What is MSD International Business GmbH and how does it relate to Merck & Co.?
MSD International Business GmbH is a non-U.S. legal entity within the MSD corporate structure. MSD operates globally under different legal names, including Merck Sharp & Dohme outside the United States and Canada. Merck & Co., Inc. is the U.S.-listed parent and reports consolidated results for the group rather than individual subsidiaries such as MSD International Business GmbH.[1]
Corporate role and geographic relevance
The entity may appear in:
- European and international patent assignments;
- Licensing and commercialization arrangements;
- Regulatory or distribution documentation;
- Intercompany ownership structures;
- Litigation records involving MSD products;
- Intellectual-property filings outside the United States.
The entity should not be treated as an independently listed pharmaceutical company. Revenue, product-market share and R&D expenditure attributed specifically to MSD International Business GmbH are not separately disclosed in Merck & Co.’s public financial reporting.
How large is MSD’s global pharmaceutical business?
Merck & Co. reported approximately $64.2 billion in 2024 sales. Pharmaceutical products represented the principal source of revenue, led by Keytruda, Gardasil/Gardasil 9 and Januvia-related products. Keytruda generated approximately $29.5 billion in 2024 sales, making it one of the largest individual pharmaceutical products globally.[1]
| Business or product |
Strategic role |
2024 position |
| Keytruda, pembrolizumab |
Oncology and immunotherapy anchor |
Approximately $29.5 billion sales |
| Gardasil/Gardasil 9 |
HPV vaccine franchise |
Approximately $8.6 billion sales |
| Animal Health |
Companion and livestock products |
More than $6 billion sales |
| Januvia/Januamet |
Diabetes franchise |
Mature, declining platform |
| Winrevair, sotatercept |
Pulmonary arterial hypertension |
Growth product launched in 2024 |
| Welireg, belzutifan |
Oncology and rare disease |
Expansion product |
| Lynparza, olaparib |
PARP inhibitor, partnered with AstraZeneca |
Established oncology product |
| Bridion, sugammadex |
Anesthesia and hospital care |
Mature hospital product |
MSD’s position is strongest in oncology and vaccines. Its position is weaker in areas where products face broad generic competition, such as diabetes, or where rival companies have larger or more diversified platforms.
What products give MSD its strongest competitive position?
Keytruda and the oncology franchise
Keytruda is MSD’s core commercial and strategic asset. Pembrolizumab is approved across a wide range of tumor types and biomarker-defined populations. Its competitive advantages include:
- Broad clinical-label coverage;
- Established physician familiarity;
- Extensive combination-trial activity;
- Use across adjuvant, neoadjuvant and metastatic settings;
- Strong commercial infrastructure;
- Combination partnerships with other oncology companies.
The principal competitors include Bristol Myers Squibb’s Opdivo, Roche’s Tecentriq, AstraZeneca’s Imfinzi, Regeneron and Sanofi’s Libtayo, and combinations involving Merck KGaA’s Bavencio.
Keytruda’s breadth creates commercial resilience but also increases exposure to patent, pricing and treatment-sequencing challenges. Rival products can compete through differentiated dosing, tumor-specific data, combination regimens or lower-cost biosimilar entry.
Gardasil and Gardasil 9
Gardasil is a leading human papillomavirus vaccine franchise. Its principal advantages are brand recognition, global regulatory approvals, clinical history and manufacturing scale. The product benefits from public-health programs and routine adolescent vaccination markets.
Competitive pressure comes from:
- National procurement pricing;
- Vaccine-budget constraints;
- Local or regional vaccine manufacturers;
- Changes in public-health recommendations;
- Manufacturing capacity limitations;
- Demand volatility by geography.
Gardasil is a biologic vaccine product, so its exclusivity analysis does not follow the same Orange Book framework used for small-molecule drugs.
Winrevair and specialty medicines
Winrevair, or sotatercept-csrk, expands MSD into pulmonary arterial hypertension. Its mechanism and clinical positioning distinguish it from conventional vasodilator-based treatments. The product faces competition from established therapies marketed by United Therapeutics, Johnson & Johnson, Bayer and other companies.
The commercial question is whether Winrevair becomes a foundational therapy used broadly across treatment lines or remains concentrated in selected patients. Its strategic value also depends on label expansion, long-term outcomes and payer treatment policies.
What patents protect MSD’s leading products?
Patent protection for MSD products is distributed across composition-of-matter, formulation, dosage, manufacturing, therapeutic-use and combination patents. The specific patent owner may be Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., MSD International Business GmbH or another affiliated entity, depending on jurisdiction and transaction history.
Keytruda patent estate
Keytruda’s U.S. patent estate has included patents covering pembrolizumab and related therapeutic uses. Examples publicly associated with pembrolizumab include:
| Patent |
Subject matter |
Strategic relevance |
| U.S. Patent No. 8,952,136 |
Pembrolizumab-related antibody claims |
Core composition protection |
| U.S. Patent No. 9,102,683 |
Pembrolizumab-related claims |
Supplementary biologic protection |
| U.S. Patent No. 10,017,575 |
Antibody and treatment-related protection |
Later-expiring estate component |
| Additional continuation patents |
Dosing, combinations and therapeutic uses |
Launch-delay and litigation leverage |
The earliest core composition patent is commonly cited as expiring in 2028, subject to patent-term adjustment, pediatric exclusivity, terminal disclaimers and jurisdiction-specific calculations. Later patents may extend protection for selected uses or dosing schedules beyond the core compound term. The Orange Book should be reviewed for current listed patents for FDA-approved Keytruda indications, while the Purple Book and patent records are relevant to biologic exclusivity analysis.[2][3]
Gardasil patent protection
Gardasil’s protection is more complex than a single small-molecule patent. Relevant rights may cover:
- Virus-like particle compositions;
- HPV type combinations;
- Adjuvant systems;
- Production and purification methods;
- Formulation and stability;
- Administration schedules;
- Manufacturing processes.
Because Gardasil is a vaccine biologic, market-entry analysis requires review of the biologics license, FDA exclusivity, patent records and potential biosimilar or interchangeable-product pathways. Patent expiration can differ by claim category and country.
Winrevair patent protection
Winrevair’s estate is expected to include patents covering:
- Sotatercept composition;
- Activin-receptor signaling modulation;
- Pulmonary arterial hypertension treatment;
- Dosing and administration;
- Formulation and manufacturing.
As a recently approved biologic, Winrevair has a longer forward exclusivity period than MSD’s mature products. Its principal near-term risk is less likely to be biosimilar entry and more likely to be clinical competition, payer controls and label-specific disputes.
When does MSD lose exclusivity on Keytruda?
Keytruda’s earliest major U.S. patent expiration exposure is generally placed around 2028, with additional patent and regulatory protections potentially affecting specific launch scenarios. A generic launch is not the relevant pathway because pembrolizumab is a monoclonal antibody. Competitors would generally pursue a biosimilar application under the Public Health Service Act rather than an ANDA under the Hatch-Waxman framework.[3][4]
Keytruda exclusivity timeline
| Period |
Event or risk |
| 2014 |
FDA approved Keytruda for an initial melanoma indication |
| 2020s |
Expansion into multiple tumor types and treatment settings |
| 2028 |
Commonly cited earliest core patent-expiration window |
| 2028 onward |
Potential biosimilar litigation and staggered launches |
| Post-2028 |
Formulation, dosing and method-of-use patents may affect selected indications |
A biosimilar may be commercially viable before every method-of-use patent expires if the applicant uses a valid carve-out, avoids protected indications or prevails in patent litigation. The practical launch date will depend on the patent list, settlement terms, injunction risk and the scope of the biosimilar label.
What is the Orange Book status of MSD products?
The Orange Book applies principally to FDA-approved small-molecule drugs and certain drug products. It does not provide the complete exclusivity picture for biologics such as Keytruda, Gardasil or Winrevair.
Products with Orange Book relevance
Januvia, Januamet and other small-molecule products associated with sitagliptin are subject to traditional small-molecule patent and generic-entry analysis. The relevant issues include:
- Listed patents and expiration dates;
- Paragraph IV certifications;
- ANDA litigation;
- Pediatric exclusivity;
- Authorized generic strategy;
- Settlement agreements;
- Product-specific regulatory exclusivity.
Keytruda, Gardasil and Winrevair require analysis through biologic regulatory records, patent litigation and the FDA Purple Book rather than the Orange Book alone.[2][3]
Which companies are challenging MSD’s leading products?
Oncology competitors
| MSD product |
Principal competitors |
Competitive basis |
| Keytruda |
Opdivo, Tecentriq, Imfinzi, Libtayo |
Efficacy, safety, tumor-specific approvals and combinations |
| Welireg |
Other renal-cell and hypoxia-pathway treatments |
Mechanism, line of therapy and label breadth |
| Lynparza |
Rubraca, Zejula and other PARP inhibitors |
Biomarker selection and combination use |
Vaccine competitors
Gardasil’s competitive set is narrower than Keytruda’s. Competition is driven more by procurement, local manufacturing, public tenders and supply reliability than by numerous branded products in the same class.
Biosimilar challengers
No FDA-approved pembrolizumab biosimilar had been identified in the FDA Purple Book through the latest publicly available records cited here. The absence of an approved biosimilar does not eliminate future risk. Large biologic products with substantial sales attract biosimilar development because even a limited share shift can produce significant revenue.
How strong is the MSD patent estate?
MSD has a strong but uneven patent estate.
Strengths
- Large patent volume across oncology, vaccines and specialty medicines;
- Multiple continuation and divisional filings;
- Broad Keytruda therapeutic-use coverage;
- Significant clinical evidence supporting method-of-use claims;
- Global regulatory and commercial scale;
- Ability to combine patent rights with licensing and settlement strategy.
Weaknesses
- Keytruda concentration creates substantial cliff exposure;
- Method-of-use claims can be narrower and easier to design around than composition claims;
- Biologic manufacturing complexity does not prevent biosimilar competition;
- Patent ownership is distributed among affiliates and partners;
- Older franchises have already entered mature or declining stages;
- Patent validity and enablement challenges can affect broad antibody claims.
Patent strength should be assessed claim by claim. A large patent count does not necessarily establish durable exclusion if the core composition patent expires, later claims are narrow, or competitors can launch with a restricted label.
What patent litigation and Paragraph IV risks affect MSD?
MSD’s small-molecule products can face Paragraph IV certifications from ANDA applicants. These disputes typically involve validity, enforceability, infringement and the scope of Orange Book-listed patents. Litigation can trigger a 30-month stay under the Hatch-Waxman framework, subject to statutory exceptions and court action.[4]
For Keytruda and other biologics, the Biologics Price Competition and Innovation Act creates a different patent-dispute structure. Biosimilar applicants may engage in the statutory patent-exchange process, while litigation can address composition, manufacturing, formulation and treatment claims.[5]
The main litigation risks are:
- Invalidity challenges against core composition claims;
- Non-infringement arguments based on biosimilar formulations or manufacturing;
- Carve-outs from protected indications;
- Challenges to formulation and dosing patents;
- Antitrust claims involving settlements or product hopping;
- Disputes over patent ownership and inventorship.
Publicly reported litigation involving a specific MSD International Business GmbH product must be distinguished from litigation involving Merck & Co. affiliates, licensees or regional distributors. The named legal entity in a complaint may not be the commercial product owner.
What licensing deals shape MSD’s competitive position?
MSD’s growth strategy relies on internal discovery, acquisitions and licensing. Important relationships include:
- AstraZeneca collaboration involving Lynparza and related commercialization rights;
- Eisai collaboration involving Lenvima;
- Strategic oncology research collaborations;
- Business-development transactions involving antibody, vaccine and specialty platforms.
Licensing arrangements can alter patent ownership, regional commercialization rights, royalty economics and litigation control. A product may be marketed by MSD while patents remain owned jointly or by a partner. Royalty obligations also reduce the economic value of gross product sales.
For competitive analysis, the key questions are who owns the core patent, who controls prosecution, who controls litigation and whether rights are exclusive by territory or indication.
What generic and biosimilar launch scenarios exist for MSD?
Scenario 1: Delayed Keytruda biosimilar entry
A biosimilar applicant may defer launch until the core patent position weakens, then enter with a broad oncology label after resolving litigation. This would expose MSD to rapid price discounts and share erosion in high-volume indications.
Scenario 2: Staggered or indication-limited entry
A competitor may launch with selected indications not covered by enforceable method-of-use patents. This would produce gradual erosion and allow MSD to preserve protected indications.
Scenario 3: Multiple biosimilar launches
Several approved biosimilars could enter near the same date. Competition would then shift from patent timing to contracting, formulary access, physician adoption and net pricing.
Scenario 4: Small-molecule generic erosion
Mature diabetes and hospital products face conventional ANDA competition. These products can experience faster price declines than complex biologics once regulatory and patent barriers fall.
How does MSD compare with Bristol Myers Squibb and AstraZeneca?
| Factor |
MSD |
Bristol Myers Squibb |
AstraZeneca |
| Oncology anchor |
Keytruda |
Opdivo and broad oncology portfolio |
Imfinzi, Tagrisso, Enhertu partnership |
| Vaccine position |
Gardasil is a major global franchise |
Limited comparable vaccine exposure |
Limited comparable vaccine exposure |
| Patent concentration |
High concentration in Keytruda |
More diversified across products |
Broad and growing oncology estate |
| Biosimilar exposure |
Significant Keytruda future risk |
Opdivo risk also material |
Multiple biologic and targeted-drug exposures |
| Growth profile |
Oncology, vaccines, Winrevair and specialty medicines |
Oncology, immunology and cardiovascular assets |
Oncology, respiratory and rare disease |
| Commercial risk |
Keytruda concentration and vaccine demand |
Portfolio integration and patent cliffs |
High development and acquisition spending |
MSD has a stronger vaccine position than its major oncology peers but greater dependence on Keytruda than a diversified portfolio comparison would suggest.
What revenue exposure does Keytruda create?
Keytruda represented roughly 46% of Merck & Co.’s 2024 sales based on reported product revenue. That concentration makes patent timing a central valuation issue.[1]
A simple exposure framework is:
| Keytruda erosion |
Approximate annual sales at risk before offsets |
| 10% |
About $3 billion |
| 25% |
About $7.4 billion |
| 50% |
About $14.7 billion |
| 75% |
About $22.1 billion |
These figures are gross exposure estimates based on 2024 sales and do not account for new indications, price changes, foreign-exchange movements, royalties, manufacturing costs or replacement revenue from newer products.
What strategic priorities matter most for MSD?
MSD’s strategic priorities are clear:
- Extend Keytruda through combinations, subcutaneous or alternative delivery approaches where commercially and clinically viable;
- Build Winrevair into a major specialty franchise;
- Expand Welireg and other oncology products;
- Protect Gardasil demand and manufacturing capacity;
- Use licensing and acquisitions to reduce dependence on Keytruda;
- Defend composition, formulation and method-of-use patents;
- Prepare contracting and lifecycle strategies before biosimilar entry;
- Preserve geographic rights in high-value markets.
The central strategic issue is transition management. MSD must convert current oncology cash flows into a portfolio with less reliance on one product before the Keytruda patent window becomes commercially active.
Key Takeaways
- MSD International Business GmbH is a legal entity within the global MSD structure, not a separately reported pharmaceutical operating company.
- MSD’s global market position is anchored by Keytruda, Gardasil and an expanding specialty portfolio.
- Keytruda generated approximately $29.5 billion in 2024 sales and represents the group’s largest concentration risk.
- Keytruda’s earliest major U.S. patent exposure is commonly placed around 2028, with later patents potentially affecting selected uses and launch timing.
- Biosimilar, rather than generic, competition is the principal future challenge for Keytruda.
- Gardasil has strong commercial and manufacturing advantages but faces procurement and public-health demand risks.
- Winrevair is MSD’s most important recent specialty launch and a key element of post-Keytruda diversification.
- Orange Book analysis is relevant to MSD’s small-molecule products, while Keytruda, Gardasil and Winrevair require Purple Book, BLA and patent-litigation analysis.
- MSD’s patent estate is broad, but its durability depends on claim scope, patent validity, ownership structure and the ability to enforce method-of-use rights.
- The largest financial risk is accelerated Keytruda erosion without sufficient replacement revenue from newer products.
FAQs
Is MSD International Business GmbH the same company as Merck & Co.?
No. MSD International Business GmbH is a legal entity within the broader MSD organization. Merck & Co., Inc. is the U.S.-listed parent that reports consolidated group results.
Does MSD International Business GmbH own the Keytruda patents?
Patent ownership varies by jurisdiction and patent family. Keytruda-related rights may be held by Merck & Co. affiliates, including Merck Sharp & Dohme entities, rather than exclusively by MSD International Business GmbH.
Can a generic company launch Keytruda after 2028?
No conventional generic launch is expected because Keytruda is a monoclonal antibody. A competing company would generally pursue a biosimilar pathway and would still face patent, regulatory and manufacturing barriers.
Are Gardasil patents listed in the Orange Book?
Gardasil is a biologic vaccine, so the Orange Book is not the principal source for its full exclusivity position. BLA records, biologic exclusivity, patent databases and litigation records are more relevant.
What is MSD’s biggest competitive vulnerability?
Keytruda revenue concentration is the largest vulnerability. A rapid biosimilar launch after core patent protection weakens could create a material revenue decline before newer products fully offset the loss.
References
-
Merck & Co., Inc. (2025). 2024 annual report and Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products. FDA.
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148, §7002.
